What You Should Know:
– COTA, a real-world oncology data and analytics company announced the launch of Vista, a large-scale automated EHR dataset to accelerate cancer research and the deployment of trusted generative AI in cancer care.
– Vista will provide biopharmaceutical companies with timely insights from real-world data sources to bring life-saving therapies to market faster. Vista uses automated data abstraction techniques, machine learning algorithms, and medical expert oversight to glean clinically relevant information from electronic medical records at scale.
How Vista Works
Unreliable data is the single largest barrier to unlocking generative AI as a breakthrough tool to transform cancer therapy for millions of patients. Vista sources data directly from the electronic medical record and COTA oncologists provide programmatic oversight of the data to ensure the information is clinically precise and relevant. This transparency is critical to power trustworthy AI tools. That information provides better insights into the holistic journey of cancer patient populations, with the goal of not only powering retrospective analyses but also enabling patient matching into clinical trials.
“Real-world data that tells a more complete story of a patient has accelerated our understanding of cancer and the development of lifesaving and life-extending therapies,” said Miruna Sasu, CEO of COTA. “Generative AI has even more potential to advance treatment options for millions of people if we can build trusted large language models for oncology. That means first curating and validating data at a fundamentally different pace and scale. That’s what we are doing with Vista.”